{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:52:51Z","timestamp":1789768371136,"version":"4.0.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,9,7]],"date-time":"2010-09-07T00:00:00Z","timestamp":1283817600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Infect Dis Rep"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s11908-010-0138-8","type":"journal-article","created":{"date-parts":[[2010,9,6]],"date-time":"2010-09-06T04:48:53Z","timestamp":1283748533000},"page":"455-464","source":"Crossref","is-referenced-by-count":49,"title":["Treatment of Resistant Enterococcal Urinary Tract Infections"],"prefix":"10.1007","volume":"12","author":[{"given":"Subramanian","family":"Swaminathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Alangaden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,7]]},"reference":[{"key":"138_CR1","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1086\/591861","volume":"29","author":"AI Hidron","year":"2008","unstructured":"\u2022 Hidron AI, Edwards JR, Patel J, et al.: Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006\u20132007. Infect Control Hosp Epidemiol 2008, 29:996\u20131011. This article provides a good overview of the magnitude of health-care associated infections caused by VRE.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"138_CR2","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1099\/mic.0.026385-0","volume":"155","author":"K Fisher","year":"2009","unstructured":"Fisher K, Phillips C: The ecology, epidemiology and virulence of Enterococcus. Microbiology 2009, 155:1749\u20131757.","journal-title":"Microbiology"},{"key":"138_CR3","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/QCO.0b013e32818be63d","volume":"20","author":"RJ Willems","year":"2007","unstructured":"Willems RJ, Bonten MJ: Glycopeptide-resistant enterococci: deciphering virulence, resistance and epidemicity. Curr Opin Infect Dis 2007, 20:384\u2013390.","journal-title":"Curr Opin Infect Dis"},{"key":"138_CR4","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2307\/30141777","volume":"19","author":"WJ Martone","year":"1998","unstructured":"Martone WJ: Spread of vancomycin-resistant enterococci: why did it happen in the United States? Infect Control Hosp Epidemiol 1998, 19:539\u2013545.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"138_CR5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S1473-3099(01)00145-1","volume":"1","author":"MJ Bonten","year":"2001","unstructured":"Bonten MJ, Willems R, Weinstein RA: Vancomycin-resistant enterococci: why are they here, and where do they come from? Lancet Infect Dis 2001, 1:314\u2013325.","journal-title":"Lancet Infect Dis"},{"key":"138_CR6","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.arcmed.2005.02.005","volume":"36","author":"GM Bearman","year":"2005","unstructured":"Bearman GM, Wenzel RP: Bacteremias: a leading cause of death. Arch Med Res 2005, 36:646\u2013659.","journal-title":"Arch Med Res"},{"key":"138_CR7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1128\/CMR.3.1.46","volume":"3","author":"BE Murray","year":"1990","unstructured":"Murray BE: The life and times of the enterococcus. Clin Microbiol Rev. 1990, 3:46\u201365.","journal-title":"Clin Microbiol Rev."},{"key":"138_CR8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1128\/AAC.36.1.121","volume":"36","author":"TL Hodges","year":"1992","unstructured":"Hodges TL, Zighelboim-Daum S, Eliopoulos GM, et al.: Antimicrobial susceptibility changes in Enterococcus faecalis following various penicillin exposure regimens. Antimicrob Agents Chemother 1992, 36:121\u2013125.","journal-title":"Antimicrob Agents Chemother"},{"key":"138_CR9","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJM200003093421007","volume":"324","author":"BE Murray","year":"2000","unstructured":"Murray BE: Vancomycin resistant enterococcal infections. New Engl J Med 2000, 324:710\u2013712.","journal-title":"New Engl J Med"},{"key":"138_CR10","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1128\/AAC.49.7.2954-2958.2005","volume":"49","author":"S Ono","year":"2005","unstructured":"Ono S, Muratani T, Matsumoto T: Mechanisms of resistance to imipenem and ampicillin in Enterococcus faecalis. Antimicrob Agents Chemother 2005, 49:2954\u20132958.","journal-title":"Antimicrob Agents Chemother"},{"key":"138_CR11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/515605","volume":"178","author":"T Rybkine","year":"1998","unstructured":"Rybkine T, Mainardi JL, Sougakoff W, et al. : Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of beta-lactam resistance. J Infect Dis 1998, 178:159\u2013163.","journal-title":"J Infect Dis"},{"key":"138_CR12","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJMoa025025","volume":"348","author":"S Chang","year":"2003","unstructured":"Chang S, Sievert DM, Hageman JC, et al.; Vancomycin-Resistant Staphylococcus aureus Investigative Team: Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003, 348:1342\u20131347.","journal-title":"N Engl J Med"},{"key":"138_CR13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1086\/502357","volume":"25","author":"DK Warren","year":"2004","unstructured":"Warren DK, Nitin A, Hill C, et al.: Occurrence of co-colonization or co-infection with vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus in a medical intensive care unit. Infect Control Hosp Epidemiol 2004, 25:99\u2013104.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"138_CR14","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/jac\/dkg352","volume":"53","author":"GG Zhanel","year":"2003","unstructured":"Zhanel GG, Laing NM, Nichol KA, et al.: Antibiotic activity against UTI isolates of VRE: results from the 2002 NAVRESS. J Antimicrob Chemother 2003, 53:382\u2013388.","journal-title":"J Antimicrob Chemother"},{"key":"138_CR15","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1001\/archinte.158.10.1127","volume":"158","author":"MJ Bonten","year":"1998","unstructured":"Bonten MJ, Slaughter S, Ambergen AW, et al.: The role of \u201ccolonization pressure\u201d in the spread of vancomycin-resistant enterococci: an important infection control variable. Arch Intern Med 1998, 158:1127\u20131132.","journal-title":"Arch Intern Med"},{"key":"138_CR16","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1016\/j.transproceed.2007.08.045","volume":"39","author":"G M\u0142ynarczyk","year":"2007","unstructured":"M\u0142ynarczyk G, Grzybowska W, M\u0142ynarczyk A, et al.: Significant increase in the isolation of glycopeptide-resistant enterococci from patients hospitalized in the transplant surgery ward in 2004\u20132005. Transplant Proc 2007, 39:2883\u20132885.","journal-title":"Transplant Proc"},{"key":"138_CR17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1053\/jhin.2002.1375","volume":"53","author":"LS Chavers","year":"2003","unstructured":"Chavers LS, Moser SA, Benjamin WH, et al.: Vancomycin-resistant enterococci: 15\u00a0years and counting. J Hosp Infect 2003, 53:159\u2013171.","journal-title":"J Hosp Infect"},{"key":"138_CR18","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/520311","volume":"26","author":"GM Lucas","year":"1998","unstructured":"Lucas GM, Lechtzin N, Puryear DW, et al.: Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis 1998, 26:1127\u20131133.","journal-title":"Clin Infect Dis"},{"key":"138_CR19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/jlts.2001.20784","volume":"7","author":"R Patel","year":"2001","unstructured":"Patel R, Allen SL, Manahan JM, et al.: Natural history of vancomycin resistant enterococcal colonization in liver and kidney transplant recipients. Liver Transplantation 2001, 7:27\u201331.","journal-title":"Liver Transplantation"},{"key":"138_CR20","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1086\/517524","volume":"195","author":"KV Singh","year":"2007","unstructured":"Singh KV, Nallapareddy SR, Murray BE: Importance of the ebp (endocarditis and biofilm-associated pilus) locus in the pathogenesis of Enterococcus faecalis ascending urinary tract infection. J Infect Dis 2007, 195:1671\u20131677.","journal-title":"J Infect Dis"},{"key":"138_CR21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/sj.bmt.1702123","volume":"25","author":"D Kapur","year":"2000","unstructured":"Kapur D, Dorsky D, Feingold JM, et al.: Incidence and outcome of vancomycin-resistant enterococcal bacteremia following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2000, 25:147\u2013152.","journal-title":"Bone Marrow Transplant"},{"key":"138_CR22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3340\/jkns.2009.46.2.123","volume":"46","author":"Y-B Se","year":"2009","unstructured":"Se Y-B, Chun H-J, Yi H-J, et al.: Incidence and risk factors of infection caused by vancomycin-resistant enterococcus colonization in neurosurgical intensive care unit patients. J Korean Neurosurg Soc 2009, 46:123\u2013129.","journal-title":"J Korean Neurosurg Soc"},{"key":"138_CR23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/jlts.2001.20784","volume":"7","author":"R Patel","year":"2001","unstructured":"Patel R, Allen SL, Manahan JM, et al.: Natural history of vancomycinresistant enterococcal colonization in liver and kidney transplant recipients. Liver Transplant 2001, 7:27\u201331.","journal-title":"Liver Transplant"},{"key":"138_CR24","unstructured":"Horan TC, White JW, Jarvis WR, et al.: Nosocomial infection surveillance, 1984. MMWR Morb Mortal Wkly Rep 1986, 35(1SS):17SS\u201329SS."},{"key":"138_CR25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0039-6060(99)70253-9","volume":"125","author":"A Fleenor-Ford","year":"1999","unstructured":"Fleenor-Ford A, Hayden MK, Weinstein RA: Vancomycin-resistant enterococci: implications for surgeons. Surgery 1999, 125:121\u2013125.","journal-title":"Surgery"},{"key":"138_CR26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1086\/650482","volume":"50","author":"TM Hooten","year":"2010","unstructured":"\u2022\u2022 Hooten TM, Bradley SF, Cardenas DD, et al.: Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2010, 50:625\u2013663. This article describes current IDSA guidelines on catheter-associated urine infections, including differentiation from colonization.","journal-title":"Clin Infect Dis"},{"key":"138_CR27","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/infdis\/172.4.993","volume":"172","author":"DK Shay","year":"1995","unstructured":"Shay DK, Maloney SA, Montecalvo M, et al.: Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995, 172:993\u20131000.","journal-title":"J Infect Dis"},{"key":"138_CR28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1399-0012.2006.00519.x","volume":"20","author":"GJ Alangaden","year":"2006","unstructured":"Alangaden GJ, Thyagarajan R, Gruber SA, et al.: Infectious complications after kidney transplantation: current epidemiology and associated risk factors. Clin Transplant 2006, 20:401\u2013409.","journal-title":"Clin Transplant"},{"key":"138_CR29","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1067\/mic.2000.106904","volume":"28","author":"AHM Wong","year":"2000","unstructured":"Wong AHM, Wenzel RP, Edmond MB: Epidemiology of bacteriuria caused by vancomycin-resistant enterococci\u2014a retrospective study. Am J Infect Control 2000, 28:277\u2013281.","journal-title":"Am J Infect Control"},{"key":"138_CR30","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/clinids\/20.5.1126","volume":"20","author":"MB Edmond","year":"1995","unstructured":"Edmond MB, Ober JF, Weinbaum DL, et al.: Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995, 20:1126\u20131133.","journal-title":"Clin Infect Dis"},{"key":"138_CR31","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1086\/313949","volume":"31","author":"JW Chow","year":"2000","unstructured":"Chow JW: Aminoglycoside resistance in enterococci. Clin Infect Dis 2000, 31:586\u2013589.","journal-title":"Clin Infect Dis"},{"key":"138_CR32","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1128\/AAC.39.9.1984","volume":"39","author":"JL Mainardi","year":"1995","unstructured":"Mainardi JL, Gutmann L, Acar JF, Goldstein FW: Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis. Antimicrob Agents Chemother 1995, 39:1984\u20131987.","journal-title":"Antimicrob Agents Chemother"},{"key":"138_CR33","doi-asserted-by":"crossref","first-page":"574","DOI":"10.7326\/0003-4819-146-8-200704170-00008","volume":"8","author":"J Gavalda","year":"2007","unstructured":"\u2022 Gavalda J, Len O, Miro JM, et al.: Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med 2007, 8:574\u2013579. Treatment of enterococcal endocarditis with ampicillin and ceftriaxone was shown to be effective, making this an option for aminoglycoside-resistant strains.","journal-title":"Ann Intern Med"},{"key":"138_CR34","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/infdis\/173.4.909","volume":"173","author":"CM Brandt","year":"1996","unstructured":"Brandt CM, Rouse MS, Laue NW, et al.: Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell wall-active agents. J Infect Dis 1996, 173:909\u2013913.","journal-title":"J Infect Dis"},{"key":"138_CR35","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/520427","volume":"29","author":"JW Warren","year":"1999","unstructured":"Warren JW, Abrutyn E, Hebel JR, et al.: Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 1999, 29:745\u2013758.","journal-title":"Clin Infect Dis"},{"key":"138_CR36","unstructured":"Macrobid (nitrofurantoin monohydrate\/macrocrystals) capsules [prescribing information]. Cincinnati, OH: Procter & Gamble Pharmaceuticals; 2009. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020064s019lbl.pdf . Accessed August 2010."},{"key":"138_CR37","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/00003495-199753040-00007","volume":"53","author":"SS Patel","year":"1997","unstructured":"Patel SS, Balfour JA, Bryson HM: Fosfomycin tromethamine: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 1997, 53:637\u2013656.","journal-title":"Drugs"},{"key":"138_CR38","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/jac\/dkq237","volume":"65","author":"ME Falagas","year":"2010","unstructured":"Falagas ME, Vouloumanou SK, Togias AG, et al.: Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010, 65:1862\u20131877.","journal-title":"J Antimicrob Chemother"},{"key":"138_CR39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/jac\/43.1.137","volume":"43","author":"PC Fuchs","year":"1999","unstructured":"Fuchs PC, Barry AL, Brown SD: Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten North American medical centres by three methods. J Antimicrob Chemother 1999, 43:137\u2013140.","journal-title":"J Antimicrob Chemother"},{"key":"138_CR40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jac\/46.1.129","volume":"46","author":"M Bonadio","year":"2000","unstructured":"Bonadio M, Meini M, Tagliaferri E, et al.: Enterococcal glycopeptide resistance at an Italian teaching hospital. J Antimicrob Chemother 2000, 46:129\u2013131.","journal-title":"J Antimicrob Chemother"},{"key":"138_CR41","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0732-8893(02)00370-X","volume":"42","author":"MB Perri","year":"2002","unstructured":"Perri MB, Hershberger E, Ionescu M, et al.: In vitro susceptibility of vancomycin-resistant enterococci (VRE) to fosfomycin. Diagn Microbiol Infect Dis 2002, 42:269\u2013271.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"138_CR42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/0036554021000026985","volume":"35","author":"NK Shrestha","year":"2003","unstructured":"Shrestha NK, Chua JD, Tuohy MJ, et al.: Antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium: potential utility of fosfomycin. Scand J Infect Dis 2003, 35:12\u201314.","journal-title":"Scand J Infect Dis"},{"key":"138_CR43","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijantimicag.2007.11.003","volume":"31","author":"F Cilli","year":"2008","unstructured":"Cilli F, Pullukcu H, Aydemir S, et al.: In vitro activity of fosfomycin tromethamine and linezolid against vancomycin-resistant Enterococcus faecium isolates. Int J Antimicrob Agents 2008, 31:297\u2013298.","journal-title":"Int J Antimicrob Agents"},{"key":"138_CR44","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1128\/AAC.00721-09","volume":"53","author":"S Maraki","year":"2009","unstructured":"Maraki S, Samonis G, Rafailidis PI, et al.: Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother 2009, 53:4508\u20134510.","journal-title":"Antimicrob Agents Chemother"},{"key":"138_CR45","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00019048-200009090-00004","volume":"9","author":"NK Shrestha","year":"2000","unstructured":"Shrestha NK, Amuh D, Goldman MP, et al.: Treatment of a complicated vancomycin-resistant enterococcal urinary tract infection with fosfomycin. Infect Dis Clin Pract 2000, 9:368\u2013371.","journal-title":"Infect Dis Clin Pract"},{"key":"138_CR46","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1086\/527442","volume":"46","author":"ME Falagas","year":"2008","unstructured":"Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008, 46:1069\u20131077.","journal-title":"Clin Infect Dis"},{"key":"138_CR47","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ijantimicag.2003.12.017","volume":"23","author":"KG Naber","year":"2004","unstructured":"Naber KG, Allin DM, Clarysse L, et al.: Gatifloxacin 400\u00a0mg as a single shot or 200\u00a0mg once daily for 3\u00a0days is as effective as ciprofloxacin 250\u00a0mg twice daily for the treatment of patients with uncomplicated urinary tract infections. Int J Antimicrob Agents 2004, 23:596\u2013605.","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 1","key":"138_CR48","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.ijantimicag.2003.09.002","volume":"23","author":"KG Naber","year":"2004","unstructured":"Naber KG, Bartnicki A, Bischoff W, et al.: Gatifloxacin 200\u00a0mg or 400\u00a0mg once daily is as effective as ciprofloxacin 500\u00a0mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. Int J Antimicrob Agents 2004, 23(Suppl 1):S41\u2013S53.","journal-title":"Int J Antimicrob Agents"},{"key":"138_CR49","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2165\/00003495-200262030-00002","volume":"62","author":"PK Linden","year":"2002","unstructured":"Linden PK: Treatment options for vancomycin-resistant enterococcal infections. Drugs 2002, 62:425\u2013441.","journal-title":"Drugs"},{"key":"138_CR50","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/clinids\/20.5.1137","volume":"20","author":"AH Norris","year":"1995","unstructured":"Norris AH, Reilly JP, Edelstein PH, et al.: Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. Clin Infect Dis 1995, 20:1137\u20131144.","journal-title":"Clin Infect Dis"},{"key":"138_CR51","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1086\/515002","volume":"27","author":"E Lautenbach","year":"1998","unstructured":"Lautenbach E, Schuster MG, Biler WB, et al.: The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus. Clin Infect Dis 1998, 27:1259\u20131265.","journal-title":"Clin Infect Dis"},{"key":"138_CR52","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1086\/323899","volume":"33","author":"PK Linden","year":"2001","unstructured":"Linden PK, Moellering RC Jr, Wood CA, et al.: Treatment of vancomycin-resistant Enterococcus faecium infections with quinipristin\/dalfopristin. Clin Infect Dis 2001, 33:1816\u20131823.","journal-title":"Clin Infect Dis"},{"key":"138_CR53","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1469-0691.2010.03214.x","volume":"16","author":"CA Arias","year":"2010","unstructured":"\u2022\u2022 Arias CA, Contreras GA, Murray BE: Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect 2010, 16:555\u2013562. This article provides a detailed review of treatment options for VRE.","journal-title":"Clin Microbiol Infect"},{"key":"138_CR54","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1345\/aph.1K561","volume":"42","author":"K Shea","year":"2008","unstructured":"Shea K, Hilburger E, Baroco A, Oldfield E: Successful treatment of vancomycin-resistant enterococcus faecium pyelonephritis with daptomycin during pregnancy. Ann Pharmacother 2008, 42:722\u2013725.","journal-title":"Ann Pharmacother"},{"key":"138_CR55","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1128\/AAC.47.12.3789-3794.2003","volume":"47","author":"FM Wagenlehner","year":"2003","unstructured":"Wagenlehner FM, Wydra S, Onda H, et al.: Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob Agents Chemother 2003, 47:3789\u20133794.","journal-title":"Antimicrob Agents Chemother"},{"key":"138_CR56","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/345744","volume":"2","author":"MC Birmingham","year":"2003","unstructured":"Birmingham MC, Rayner CR, Meagher AK, et al.: Linezolid for the treatment of multidrug-resistant, gram positive infections: experience from a compassionate-use program. Clin Infect Dis 2003, 2:159\u2013168.","journal-title":"Clin Infect Dis"},{"key":"138_CR57","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1086\/523276","volume":"28","author":"JM Pogue","year":"2007","unstructured":"Pogue JM, Paterson DL, Pasculle AW, Potoski BA: Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol 2007, 28:1382\u20131388.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"138_CR58","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1517\/13543784.13.9.1159","volume":"13","author":"BI Eisenstein","year":"2004","unstructured":"Eisenstein BI: Lipopeptides, focusing on daptomycin, for the treatment of gram-positive infections. Expert Opin Investig Drugs 2004, 13:1159\u20131169.","journal-title":"Expert Opin Investig Drugs"},{"issue":"Suppl 1","key":"138_CR59","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.ijantimicag.2004.02.002","volume":"24","author":"FM Wagenlehner","year":"2004","unstructured":"Wagenlehner FM, Naber KG: New drugs for gram-positive uropathogens. Int J Antimicrob Agents 2004, 24(Suppl 1):S39\u2013S43.","journal-title":"Int J Antimicrob Agents"},{"key":"138_CR60","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1128\/AAC.32.1.81","volume":"32","author":"FL Sapico","year":"1988","unstructured":"Sapico FL, Ginunas VJ, Canawati HN, Montgomerie JZ: LY146032, alone and in combination with gentamicin, for the treatment of enterococcal pyelonephritis in the rat model. Antimicrob Agents Chemother 1988, 32:81\u201383.","journal-title":"Antimicrob Agents Chemother"},{"key":"138_CR61","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1086\/522656","volume":"10","author":"CA Arias","year":"2007","unstructured":"Arias CA, Torres HA, Singh KV, et al.: Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin Infect Dis 2007, 10:1343\u20131346.","journal-title":"Clin Infect Dis"},{"key":"138_CR62","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1086\/444459","volume":"8","author":"MP Stevens","year":"2005","unstructured":"Stevens MP, Edmond MB: Endocarditis due to vancomycin-resistant enterococci: case report and review of the literature. Clin Infect Dis 2005, 8:1134\u20131142.","journal-title":"Clin Infect Dis"},{"key":"138_CR63","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/01.idc.0000144898.12957.eb","volume":"12","author":"KG Naber","year":"2004","unstructured":"Naber KG, Eisenstein BI, Tally FP: Daptomycin versus ciprofloxacin in the treatment of complicated urinary tract infection due to gram-positive bacteria. Infect Dis Clin Pract 2004, 12:322\u2013327.","journal-title":"Infect Dis Clin Pract"},{"key":"138_CR64","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ijantimicag.2008.11.003","volume":"33","author":"L Fisher","year":"2009","unstructured":"Fisher L, North D: Effectiveness of low-dose daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections. Int J Antimicrob Agent 2009, 33:493\u2013494.","journal-title":"Int J Antimicrob Agent"},{"key":"138_CR65","unstructured":"Tygacil [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals; 2010. Available at http:\/\/www.wyeth.com\/content\/showlabeling.asp?id=491 . Accessed August 2010."},{"key":"138_CR66","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.diagmicrobio.2005.06.001","volume":"52","author":"DJ Hoban","year":"2005","unstructured":"Hoban DJ, Bouchillon SK, Johnson BM, et al.; Tigecycline Evaluation and Surveillance Trial (TEST Program) Group: In vitro activity of tigecycline against 6792 gram-negative and gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005, 52:215\u2013227.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl 5","key":"138_CR67","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1086\/431675","volume":"41","author":"EJ Ellis-Grosse","year":"2005","unstructured":"Ellis-Grosse EJ, Babinchak T, Dartois N, et al.; Tigecycline 300 cSSSI Study Group; Tigecycline 305 cSSSI Study Group: The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005, 41(Suppl 5):S341\u2013S53.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 5","key":"138_CR68","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.1086\/431676","volume":"41","author":"T Babinchak","year":"2005","unstructured":"Babinchak T, Ellis-Grosse E, Dartois N, et al.; Tigecycline 301 Study Group; Tigecycline 306 Study Group: The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005, 41(Suppl 5):S354\u2013S67.","journal-title":"Clin Infect Dis"},{"key":"138_CR69","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/jac\/dkq116","volume":"65","author":"DE Nix","year":"2010","unstructured":"Nix DE, Matthias KR: Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation. J Antimicrob Chemother 2010, 65:1311\u20131312.","journal-title":"J Antimicrob Chemother"},{"key":"138_CR70","unstructured":"Vibativ (telavancin) for injection [prescribing information]. South San Francisco, CA: Astellas Pharma; 2009. Available at http:\/\/www.vibativ.com . Accessed August 2010."},{"key":"138_CR71","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1128\/AAC.44.11.3017-3021.2000","volume":"44","author":"A Lefort","year":"2000","unstructured":"Lefort A, Saleh-Mghir A, Garry L, et al.: Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis. Antimicrob Agents Chemother 2000, 44:3017\u20133021.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Current Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-010-0138-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11908-010-0138-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-010-0138-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:22:14Z","timestamp":1559434934000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11908-010-0138-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,7]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["138"],"URL":"https:\/\/doi.org\/10.1007\/s11908-010-0138-8","relation":{},"ISSN":["1523-3847","1534-3146"],"issn-type":[{"value":"1523-3847","type":"print"},{"value":"1534-3146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,7]]}}}